Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings. Povetacicept, a dual inhibitor of B-cell activating factor ...

Most Medicaid enrollees who lost coverage during the unwinding were removed for procedural reasons, and expansion adults will ...

Anti-CGRP antibody exposure near conception was linked to higher spontaneous abortion risk in migraine, while propranolol was not, a cohort study found. Exposure to anticalcitonin gene-related peptide ...

Combined MRI and ultrasound raised sensitivity for bowel and uterosacral ligament endometriosis but reduced specificity in a prospective cohort study. Investigators at Stockholm South General Hospital ...

Dr. Haumschild compares SGLT2 inhibitors and GLP-1 receptor agonists as evidence in both classes keeps evolving. He acknowledges GLP-1s carry real budget impact that payers cannot ...

The influx of novel therapies is expanding treatment options for patients with cancer, but distance, infrastructure, and ...

In “Immunotherapy in MSI-High and dMMR mCRC,” Dr. Strickler discusses how immune checkpoint inhibition has reshaped treatment ...

Real-world evidence indicates that longer biologic dosing intervals are associated with higher persistence and fewer ...

Approximately 4.3 million Medicare beneficiaries will have their plans terminated at the end of 2026—including 3.1 million ...

Among patients with essential thrombocythemia, higher average ropeginterferon alfa-2b exposure was associated with greater JAK2V617F allele burden reduction at 6 or 7 months (P = .021).

Among youths who misused each drug class, those with depression were more likely to cite helping with feelings and emotions as their main reason for misusing opioid analgesics (10.2% vs 3.7%; P = .01) ...

The National Comprehensive Cancer Network (NCCN), the alliance of 34 leading US cancer centers whose clinical practice guidelines inform what payers cover in health plans,¹ today ...